शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
LYKALABSNSELyka Labs Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Wed, 12 Nov, 2025 · 14:32 IST

Lyka Labs Q2 FY26 results show strong revenue and PAT growth

Revenue growth above 20%Profit growth above 25%Results View source PDFExplain this filing

LYKALABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-1.6%Reaction day
₹93.00
prior close
₹94.00
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.9%-2.5% vs market
Pharmaceuticals peers, median of 157sector+0.8%-2.4% vs sector

On the reaction day the stock moved 2.5 pts less than Nifty Microcap 250 and 2.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-0.9
10m
-2.7
15m
-1.6
30m
-1.1
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-1.6+0.9-2.5+0.8-2.4
Next day
-3.8+0.8-4.6+0.5-4.3
2d
-5.6+0.7-6.3+0.4-6.0
3d
-7.7+1.3-9.1+0.6-8.3
4d
-10.8+0.5-11.3-0.1-10.6
5d
-13.8+0.4-14.1-0.6-13.2
1w
-9.1-1.5-7.7-1.2-8.0
15d
-9.9-2.4-7.5-1.8-8.2
1m
-16.7-4.4-12.3-2.6-14.2
2m
-15.6-7.2-8.4-5.4-10.3
3m
-24.5-5.0-19.5-5.7-18.7
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lyka Labs Q2 FY26 results show strong growth. Standalone revenue from operations rose to 6,214.68 lakhs (Q2 FY25: 4,115.51). H1 FY26 total income was 13,704.09 lakhs, about 90 percent higher YoY. Q2 PAT jumped to 422.24 lakhs (Q2 FY25: 81.42). H1 PAT turned positive at 822.72 lakhs versus a loss of 281.27 lakhs. Consolidated results mirrored this trend. Auditor gave an unqualified opinion. An ECL provision of 484.03 lakhs was booked on international trade receivables.

Likely market impact

Strong quarterly growth and turnaround from loss signal improving business. Watch for recovery in international receivables after ECL provision.